Site icon Duncan Bucknell

India, TRIPS, pharmaceuticals and patents

Last week there was some fantastic discussion at Spicy IP and here at IP ThinkTank about the Novartis Glivec case.  (See also the comments at IP Unlimited which seem to suggest that there may be no WTO proceedings, at least by Switzerland.)

A couple of weeks ago I was fortunate enough to listen to a podcast by Shamnad Basheer (from Spicy IP) on India and TRIPS compliance.  As he has repeatedly done on Spicy IP, in the podcast, Shamnad makes some prophetic statements about how the Novartis litigation is likely to turn out. 

The podcast is also packed with useful background information about the Indian pharmaceutical and patent systems. 

I highly recommend it.

Exit mobile version